BK0025 Animal Health II
- 679.095
- +1.055+0.16%
Placo (603566) 2023 Report & 2024 Quarterly Report Review: Pig Seedling, Chemical and Other Businesses Under Pressure Await Cycle Recovery and Operating Inflection Point
Biotech Co., Ltd. (600201): Non-oral products continue to gain strength and profits continue to improve
Ruipu Biotech (300119): Continuously promote the upgrading of the marketing system and accelerate the growth of the livestock and pet sector
Zhongmu Co., Ltd. (600195): Pharmaceuticals and chemicals bucked the trend and reduced investment income dragged down the year-on-year decline in performance
Ruipu Biotech (300119): The three major business segments are driving the same momentum, and performance is growing against the trend
Ke Qian Biology (688526): Overall performance is under pressure and waiting for demand to pick up in the post-cycle
Biotech Co., Ltd. (600201): Steady growth in the face of adversity, R&D investment reaps rewards
Placo (603566): The pig breeding business is under pressure in the short term, the pig cycle reverses, and the future is bright
Keqian Biology (688526): Demand pressure is dragging down performance and is expected to take the lead in benefiting from rising pig prices
Huisheng Biotech (300871): Multiple factors influence short-term performance under pressure, and the recovery in farming sentiment drives a sharp rise in business volume and price
China Animal Husbandry Co., Ltd. (600195): Main business resumes growth. Chemicals and vaccines have potential for growth
Bio Co., Ltd. (600201): Business quality continues to improve, and new products can be expected to be launched
Ke Qian Biology (688526): Downstream sluggish performance is temporarily under pressure, research reserves are abundant, and growth can be expected
Zhongmu Co., Ltd. (600195): Animal insurance's main business bucked the trend and investment income declined in the short term
Zhongmu Co., Ltd. (600195): Steady management, ongoing research and accumulation awaiting the inflection point of the cycle
Keqian Biology (688526) First Coverage Report: Product Strength+R&D Strength Building Core Competitiveness of Leading Companies Without Forced Exemption of Pig Seedlings
Ke Qian Biology (688526): Year-on-year decline in profit, waiting for post-cycle sentiment to recover
Ruipu Biotech (300119): Positive profit growth in Q1, improvement in profit quality
Biotech Co., Ltd. (600201): Improving profitability, R&D investment entering the harvest period
China Post Securities released a research report on April 28 stating that Placo (603566.SH) was rated to increase its holdings. The main reasons for the rating include: 1) Comments: Pig seedlings are a drag and management efficiency is improved; 2) Produc